A review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harm

Blockman, MCohen, KDe Waal, RGray, AKredo, TMaartens, GNel, JParrish, ARees, HReubenson, G2025-01-042025-01-042020-09-03https://hdl.handle.net/11288/597995enAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Low molecular weight heparinThromboembolismUnfractionated heparinAnticoagulantVenousA review of the optimal dose of either unfractionated heparin or low molecular weight heparin in the prevention of venous thromboembolism in patients with severe COVID-19: Evidence review of the clinical benefit and harmTechnical Report